Michael, Ph I & II ? You mean CDAD, of course. PK is in phase III.
See www.synsorb.com.
But there have been no news releases via CNW portfolio email service, nor by stockwatch email service.
And nothing (I just checked) on the web page www.synsorb.com and nothing in metacrawler.
So it looks like a good time to accumulate a bit more synsorb. I despair of getting back in at $10.
The chart shows it to be going sidewise. Unless somebody sues the synsorb outfit, or a key researcher goes berserk, it has nowhere to go but up.
Antibiotics continue to grow more useless and expensive---Toronto local hospital has a VRE (vancomycin resistant enterococcus?) outbreak. Van. is a last resort, and very expensive. Scary. A superscrub team had to be called in.
Local paper had article on IBS: Crohn's disease, compared to ulcerative colitis---yecch, those colostomy diseases----seems to be an autoimmune reaction condition. While I would wish for a Synsorb magic bullet for such as Crohn's disease (lip-to-stomach-to-anus inflammation, and fistulas, chronic), this is highly unlikely. I mean, your body attacks your gut; is there a toxin to dispose of?
Meanwhile, the basic principles of toxin-specific polysaccs for gobbling up ANY toxin, represent a brilliant advance in medicine. Makes the allopathic idiocies of pharmaceuticals look very feeble. Synsorb may not be able to patent all the toxin-eaters, in which case it will have rivals shortly. (Synsorb could not possibly defend a patent on the generic idea of a non-specific agent to eat toxins.)
Still, this junior firm has the best concept I have ever seen in the medical field, for a long-term money-spinner. I hope they have a poison pill to prevent takeovers. |
